Latest News - #State research center of Virology and biotechnology "Vector"

In the center "Vector" called the validity of the immunity from COVID-19

Titers of antibodies have been ill with the coronavirus in the form of light are only a few months, the question of whether they get sick in the second wave, remains open, said head of the laboratory of vector systems of the center "Vector" Ilnaz Gimatdinov.

"If it really were so, it would be good, but, unfortunately, at the moment, epidemiological studies indicate the reverse situation. When people perebolet mild, antibody titers persist for several months, and then disappear," said Gimatdinov the TV channel "Russia 24", answering the question, whether he agrees with the fact that by the time mass vaccination, the mankind can acquire herd immunity and vaccination will lose meaning.

The CPS told about the vaccine center Vector from COVID-19

The vaccine for coronavirus, developed by the center "Vector", has in its composition of the biological agent, so the number of adverse reactions from its use are minimal, said the head of Rospotrebnadzor Anna Popova.

"The vaccine is unlike any other, because it is we have a peptide that is not responsible of the biological agent in any part and in this regard is absolutely reactogenna", - said Popov on the virtual Symposium "the Impact of the pandemic COVID-19 and HIV to achieve the objective of sustainable development".

"Vector" has received permission to start clinical trials of a vaccine against COVID-19

Center "Vector" has received permission to conduct clinical trials of a vaccine against coronavirus, told in the press service of Rospotrebnadzor.

"The first volunteers will be vaccinated on 27 July", — is spoken in the message.

"Vector" will begin clinical trials of a vaccine against coronavirus 15 July

The head of Rospotrebnadzor Anna Popova said that preclinical studies of the vaccine from COVID-19 in the center "Vector" was completed July 15, is scheduled to begin testing on volunteers.

"Colleagues have done preclinical studies. They were successful. And we almost have every reason to be confident that it will, as we promised, July 15, we expect to enter the clinic," she said in an interview Naila Asker-zade, the TV channel "Russia 1", in response to a question.

The Director of "Vector" to investigate the vaccine COVID will begin on volunteers

Clinical studies of the vaccine against coronavirus in the center "Vector" will start with a group of 10 people aged 18 to 30 years, and later in the study will involve volunteers under the age of 60 years, said in an interview with RIA Novosti Director of the center for Rinat Maksyutov.

He noted that the decision about vaccination for the population can be taken only after final confirmation of safety and efficacy of the vaccine, its registration.

Clinical studies of the vaccine from COVID-19 plan to start July 15

The study of vaccines against coronavirus infection in humans in the centre "Vector" is scheduled to begin July 15, the volunteers have already been selected, said General Director of "Vector" Rinat Maksyutov.

"We expect to start clinical trials on July 15. In clinical studies, will bring together 300 volunteers. The work already undertaken on their selection, they fully comply with all the requirements," - said the native in an interview with RIA Novosti.

Called the number of doses of vaccine for generating immunity to COVID-19

For the formation in Russia of collective immunity to the coronavirus will require about 70 million doses of vaccine, said the General Director of the scientific center "Vector" Rinat Maksyutov, the TV channel "Russia 1".

"Will be determined by the number of doses you need in order to vaccinate the required minimum number of people to form a strong collective immunity. According to our estimates, it will be about 70 million doses of vaccine," said a virologist.

In the "Vector" told about the trials of a vaccine against the coronavirus in animals

Animals that have experienced a vaccine against coronavirus, responded well to it, has told on air "Russia 1" the Director of the center "Vector" Rinat Maksyutov.

"In the framework of laboratory tests of the lower primates have also been infected with the novel coronavirus. The results were, they model the infection as a person. There are a significant number of asymptomatic cases, i.e. when the virus is we can only control warusawithana in a smear using PCR method", — he said.

In "Vector", said the clinical trials of a vaccine against COVID-19

The General Director of the scientific center "Vector" Rinat Maksyutov said that to begin clinical trials of a vaccine against COVID-19 will be held in late June - early July and be completed in mid-September.

He noted that additional speed on a vaccine is not required because it is impossible to forget about the basic principles of vaccination - not to harm and not to stick a useless product.